Sanofi and evotec reached 250 million euro strategic cooperation

Source: Biovalley March 23, 2015 recently, Sanofi and evotec concluded a five-year strategic alliance negotiation and agreed to provide 250 million euros for investment, including 40 million euros in cash advance Evotec will receive Sanofi's facilities and support in Toulouse to support drug research and development cooperation It includes screening and identification of preclinical candidate drug molecules together with Biotechnology Department, venture capital and academic partners Evotec said it will provide long-term new drug research and development services for Sanofi in the next five years The service center is a small molecule screening platform in Toulouse and will take over Sanofi's global compound screening database Adhering to the principle of "innovation and breakthrough", the two companies will combine their respective databases and provide screening resources to evotec's business partners to create a large screening platform of about 1.7 million compound molecules In addition, evotec and Sanofi will jointly promote tumor related portfolio investment projects, including five advanced clinical projects on experimental new drugs and stage investment for further research before the cooperation Werner lanthaler, evotec's chairman, said the partnership supports both sides' long-term strategic development plans and creates significant value for shareholders without dilution of capital Meanwhile, Elias Zerhouni, global R & D chairman of Sanofi, also said that the cooperation between the two will create more opportunities for employees in the industry and contribute to the local ecology of the industry